Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer – A subgroup analysis of the pivotal NAPOLI-1 trial

National Cancer Institute. Cancer Stat Facts: Pancreas Cancer

World Health Organization International Agency for Research on Cancer

Wang, 2014, National trends in pancreatic cancer outcomes and pattern of care among Medicare beneficiaries, 2000 through 2010, Cancer, 120, 1050, 10.1002/cncr.28537

Rahib, 2014, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res, 74, 2913, 10.1158/0008-5472.CAN-14-0155

Jonsdottir, 2018, Incidence, diagnostic, treatment and outcome of patients diagnosed with cancer of the pancreas during 1986-2009: a population-based study, Scand J Gastroenterol, 53, 100, 10.1080/00365521.2017.1390598

Sun, 2014, Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981-2010, Sci Rep, 4, 6747, 10.1038/srep06747

Sehgal, 2014, Pancreatic cancer survival in elderly patients treated with chemotherapy, Pancreas, 43, 306, 10.1097/MPA.0000000000000091

van der Geest, 2017, Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer, Cancer Med, 10.1002/cam4.1240

Conroy, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, 1817, 10.1056/NEJMoa1011923

Lee, 2013, 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy, Chemotherapy, 59, 273, 10.1159/000356158

Zijlstra, 2018, Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands, Acta Oncol, 10.1080/0284186X.2018.1470330

Ducreux, 2015, Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 26, v56, 10.1093/annonc/mdv295

Frakes, 2015, Resected pancreatic cancer outcomes in the elderly, J Geriatr Oncol, 6, 127, 10.1016/j.jgo.2014.11.005

van der Geest, 2016, Pancreatic cancer surgery in elderly patients: balancing between short-term harm and long-term benefit. A population-based study in the Netherlands, Acta Oncol, 55, 278, 10.3109/0284186X.2015.1105381

Von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N Engl J Med, 369, 1691, 10.1056/NEJMoa1304369

Lambert, 2017, Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions, Therap Adv Gastroenterol, 10, 631, 10.1177/1756283X17713879

Gilabert, 2017, How to treat pancreatic adenocarcinoma in elderly: how far can we go in 2017?, J Geriatr Oncol, 8, 407, 10.1016/j.jgo.2017.08.007

Kipps, 2017, Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy, Ther Adv Med Oncol, 9, 159, 10.1177/1758834016688816

Wang-Gillam, 2016, Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial, Lancet, 387, 545, 10.1016/S0140-6736(15)00986-1

Baldini, 2017, Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis, Pancreatology, 17, 146, 10.1016/j.pan.2016.12.009

Drummond, 2006, Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy, Cancer Res, 66, 3271, 10.1158/0008-5472.CAN-05-4007

Kalra, 2014, Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion, Cancer Res, 74, 7003, 10.1158/0008-5472.CAN-14-0572

Sieber, 2007, The elderly patient- who is that?, Internist (Berl), 48, 1192

Castel-Kremer, 2018, An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma, J Geriatr Oncol, 9, 373, 10.1016/j.jgo.2018.03.007

Oettle, 2014, Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial, J Clin Oncol, 32, 2423, 10.1200/JCO.2013.53.6995

Ohkawa, 2015, Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer, Br J Cancer, 112, 1428, 10.1038/bjc.2015.103

Gill, 2014, PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT), J Clin Oncol, 32, 10.1200/jco.2014.32.15_suppl.4022